GlassScriptPhysician profile
Tagrid Adili
NPI 1093820417
$13,359.51
in general payments reported to CMS, 2019-2025
54 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,000 · 2020: $1,591 · 2021: $1,028 · 2022: $2,320 · 2023: $1,368 · 2024: $2,963 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,266 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,266.49 |
| Education | $153.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,361.39 | 2021-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $955.14 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Biogen, INC. | $839.95 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Genzyme Corporation | $764.76 | 2019-2024 | |
| Harmony Biosciences LLC | $650.64 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $626.83 | 2019-2025 | |
| Emd Serono, INC. | $626.38 | 2019-2025 | Mavenclad |
| Eisai INC. | $572.24 | 2024-2025 | |
| Amgen INC. | $562.97 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $561.28 | 2019-2025 | Ultomiris |
| Ucb, INC. | $538.10 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $526.07 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $437.29 | 2019-2025 | |
| Adamas Pharmaceuticals, INC. | $415.37 | 2019-2021 | |
| Pfizer INC. | $379.47 | 2019-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tagrid Adili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.